We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Plasma exchange as a tool for removal of bevacizumab: Highlighting application for urgent surgery.
- Authors
Neth, Bryan J; Winters, Jeffrey L; Sairaj, Revathi Thirumushi; Loron, Ali Gharibi; Rahman, Masum; Hirte, Renee; Riviere-Cazaux, Cecile; Ruff, Michael W; Burns, Terry C
- Abstract
Background Bevacizumab is commonly used to manage cerebral edema associated with brain tumors. However, its long half-life poses challenges for patients requiring urgent surgery due to wound complications. We present a case of utilizing therapeutic plasma exchange (TPE) to remove bevacizumab in a patient with recurrent glioblastoma requiring urgent surgery. Methods A 58-year-old male with recurrent glioblastoma, IDH-wildtype, presented with clinical and radiographic concern for ventriculitis requiring urgent wound washout only 4 days after his last bevacizumab infusion. TPE was performed for 3 sessions after surgery using a centrifugation-based cell separator. Replacement fluids included normal serum albumin, normal saline, and fresh frozen plasma. Bevacizumab levels were quantified using an enzyme-linked immunoabsorbent assay before and after each TPE session. Results TPE effectively removed bevacizumab, enabling safe surgery without new complications. Plasma bevacizumab levels decreased from 1087.63 to 145.35 ng/mL (13.4% of original) by the end of the last TPE session. This decline is consistent with nearly 3 half-lives, which compares favorably to the expected timeline of natural decline given the 21-day half-life. Conclusions We report a complex clinical scenario of a patient requiring urgent wound washout 4 days after last bevacizumab infusion for CNS infection. Surgery was successfully performed without new complications with use of TPE to remove bevacizumab immediately following surgery. This case highlights the feasibility of this approach, which may be utilized effectively in patients requiring surgery after having recently received bevacizumab.
- Subjects
BEVACIZUMAB; PLASMA products; CENTRIFUGATION; SERUM albumin; PLASMA exchange (Therapeutics); CEREBRAL edema
- Publication
Neuro-Oncology Practice, 2023, Vol 10, Issue 6, p592
- ISSN
2054-2577
- Publication type
Article
- DOI
10.1093/nop/npad053